

This is a repository copy of *Identification of novel bacteriophages with therapeutic potential targeting Enterococcus faecalis*.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/151413/

Version: Published Version

Article:

Al-Zubidi, M., Widziolek, M., Court, E.K. et al. (10 more authors) (2019) Identification of novel bacteriophages with therapeutic potential targeting Enterococcus faecalis. Infection and Immunity. ISSN 0019-9567

https://doi.org/10.1128/iai.00512-19

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



1 Identification of novel bacteriophages with

2 therapeutic potential targeting *Enterococcus*

3 faecalis

- 4 Al-Zubidi, M¹, Widziolek, M^{1,3}, Court, E.K.¹, Gains, A.F.¹, Smith, R.E.², Ansbro, K¹, Alrafaie, A¹,
- 5 Evans, C⁴, Murdoch, C¹, Mesnage, S², Douglas, C.W.I¹, Rawlinson, A.¹ & Stafford, G.P^{1*}

6

- 7 Affiliations:
- 1- Integrated BioSciences, School of Clinical Dentistry, University of Sheffield, 19 Claremont 8 9 Crescent, Sheffield, S10 2TA, UK 2- Department of Molecular Biology and Biotechnology, University of Sheffield, Firth Court, 10 Western Bank, Sheffield, S10 2TN, UK 11 12 3- Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland. 13 4- Department of Chemical and Biological Engineering, The University of Sheffield, Mappin 14 Street, Sheffield S1 3JD, UK 15

Downloaded from http://iai.asm.org/ on October 2, 2019 at PERIODICALS OFFICE, MAIN LIBRARY, UNIVERSITY OF SHEFFIELD

- 16
- 17 Corresponding author: Dr Graham Stafford, Integrated BioSciences, School of Clinical
- 18 Dentistry, University of Sheffield, 19 Claremont Crescent, Sheffield, S10 2TA, UK
- 19 Email: g.stafford@sheffield.ac.uk
- 20 **Tel:** +44 114 2254913

21

22 Abstract

23 The Gram-positive opportunistic pathogen Enterococcus faecalis is frequently responsible for 24 nosocomial infections in humans and represents one of the most common bacteria isolated from 25 recalcitrant endodontic (root canal) infections. E. faecalis is intrinsically resistant to several 26 antibiotics routinely used in clinical settings (such as cephalosporins and aminoglycosides) and 27 can acquire resistance to vancomycin (vancomycin resistant enterococci, VRE). The resistance 28 of E. faecalis to several classes of antibiotics and its capacity to form biofilms cause serious 29 therapeutic problems. In this paper, we report the isolation of several bacteriophages that target 30 E. faecalis strains isolated from the oral cavity of patients suffering root-canal infections. All 31 phages isolated were Siphoviridae with similar tail lengths (200-250 nm) and icosahedral heads. 32 The genome sequences of three isolated phages were highly conserved with the exception of predicted tail protein genes that diverge in sequence, potentially reflecting host range. The 33 properties of the phage with the broadest host-range (SHEF2), was further characterised. We 34 35 showed that this phage requires interaction with components of the major and variant region 36 Enterococcal polysaccharide antigen (Epa) to engage in lytic infection. Finally, we explored the therapeutic potential of this phage and showed that it can eradicate E. faecalis biofilms formed 37 38 in vitro on a standard polystyrene surface but also on a cross-sectional tooth-slice model of endodontic infection. We also show that SHEF2 cleared a lethal infection of zebrafish when 39 40 applied in the circulation. We therefore propose that the phage described in this study could be 41 used to treat a broad range of antibiotic resistant *E. faecalis* infections.

42

43

44 Introduction

45 Enterococcus faecalis is a common nosocomial pathogen that is a frequently isolated 46 from the blood stream and wound infections (1, 2). In some cases, the clinical outcomes are 47 poor due to the limited choices of effective antimicrobial therapy and colonisation by 48 vancomycin-resistant enterococci (VRE). One example is E. faecalis strain V583, which was the 49 first of the vancomycin-resistant *E. faecalis* clinical isolates to be sequenced (3, 4). In addition 50 E. faecalis is commonly recovered from chronic periapical or root canal infections associated with failed endodontic therapy (5, 6). It has been proposed that this is associated with their 51 52 ability to (i) live and survive in the presence of several commonly used root canal antiseptic 53 irrigants (e.g., calcium hydroxide) (7), (ii) tolerate prolonged periods of starvation (8), (iii) form 54 biofilms (9) and (iv) acquire antibiotic resistance (10, 11) -together this indicates that new therapeutic approaches are necessary. 55

56 Bacteriophage therapy has recently re-emerged as an attractive alternative antimicrobial 57 strategy to treat antibiotic resistant biofilm forming pathogens. In some infections such as those 58 associated with burn wounds caused by *Pseudomonas aeruginosa* and *Staphylococcus aureus*. 59 phage therapy is now considered an option for topical application (12). Furthermore, in the 60 United States, the FDA recently approved a phage-based phase I clinical trial against P. 61 aeruginosa. Staphylococcus and Esherichia coli in chronic venous leg ulcers, illustrating that treatment using a phage cocktail was associated with no adverse reaction (13). For example, 62 63 phase II clinical trials in Europe using phage therapy against chronic otitis externa caused by P. 64 aeruginosa infection have been conducted with successful results (14). Excitingly, phage were also used intravenously in 2019 to cure a disseminated Mycobacterium abscessus infection in 65 66 a 15-vear old in the UK (15)

E. faecalis lytic phages have been previously isolated using indicator strains of animal origin (16, 17), non-oral human isolates and lab strains (18-21). Here, we set out to isolate

bacteriophages targeting *E. faecalis* strains of oral origin, isolated either directly from endodontic infections or from mouthwashes of patients receiving endodontic treatment, and from oral lesions sourced from a range of oral microbiology laboratories around Europe. A range of tailed phages were isolated from a wastewater treatment plant and characterized. We report their therapeutic potential against *E. faecalis* strains forming biofilms and their capacity to eradicate systemic infection in a zebrafish model of infection. Overall our data further highlight that phages have great potential as therapeutic adjuncts in oral and other infections.

76

77 Materials and methods

Bacterial Strains used for bacteriophage screening. Bacterial strains used in these
investigations and their sources are listed in Table 1 (22). *Enterococcus* strains were grown
aerobically with 5% CO₂ at 37°C on brain heart infusion (BHI) agar (OXOID, UK).

Bacteriophage isolation. Bacteriophages were isolated from wastewater collected from the 81 82 inlet of a water treatment plant in the Sheffield area (UK) that treats both industrial and domestic wastewater. The water was filtered through 3M filter paper on-site to remove particles but was 83 not treated chemically or biologically. Samples were immediately brought to the laboratory and 84 85 centrifuged 7,000 x g for 15 min to remove remaining debris. The resulting supernatant was then passed through a 0.45 μm filter (Sartorius, Germany) before 200 ml of sample were further 86 centrifuged at 35,000 x g for 90 min to pellet any phage particles. The pellets were carefully 87 88 resuspended overnight in 2 ml of SM buffer (1 M Tris-HCl Buffer pH 7.4 with 5 M NaCl, 1 M MgSO₄ and 1% Gelatin) at 4°C. 10 μ I of the suspended sample was spotted on to a double 89 layer agar plate. The bottom agar was composed of BHI solid agar supplemented with 5% (v/v) 90 91 horse serum (OXOID. UK) and was overlaid with 3-4 ml of molten BHI soft agar (0.7%) containing 200 µl of test bacterial strain (overnight culture inoculum, OD₆₀₀ ~ 2). Any formed 92 plaques were picked using a sterile Pasteur pipette, deposited in 1 ml SM buffer and incubated 93

Infection and Immunity

 \triangleleft

overnight at 4°C before filtering through a 0.45 µm syringe filter. Isolated phage were then
expanded by infection using 100 µl of this with 200 µl of exponential growth phase indicator
bacteria for 10 minutes before mixing with 2-3 ml soft agar overlay (SAO) and overnight
incubation at 37°C. All phage were purified using three consecutive rounds from single-plaques.
The plaques from the third round were then re-suspended in SM buffer containing 0.1% (v/v)
chloroform and stored at 4°C.

Phage stock preparations. In order to prepare a working phage stock with known plaque forming unit numbers (PFU), 40 ml exponential growth indicator bacteria was infected with 100 µl of stored phage suspension, incubated for three hours at 37°C to allow phage to multiply and increase in number. The broth was then centrifuged at 7,000 xg for 15 min and passed through a 0.45 µm filter. Serial dilutions from the resultant broth was used in triplicate for plating in overlayer SAO as previously described and PFU/ml for each isolated phage calculated.

106 Transmission electron microscopy. Purified phage particles in SM buffer were placed onto 107 carbon-coated copper grids and negatively stained with 2% (wt/vol) uranyl acetate for 1 min. 108 Particles were visualised using a FEI Tecnai G2 Spirit Transmission Electron Microscope at an 109 accelerating voltage of 80kV at the Electron Microscopy Unit in Sheffield. Electron micrographs were recorded using a Gatan Orius 1000 digital camera and Digital Micrograph software. To 110 111 observe the phage along with bacteria, 1 ml exponentially growing cells were infected with phage at multiplicity of infection (MOI) of 1 for 30 min, after centrifugation at 7000 xg for 10 min, 112 the pellet was re-suspended with 1 ml 3% glutaraldehyde for one hour (room temperature) and 113 114 examined by TEM as described above.

Bacteriophage concentration by precipitation with Polyethylene Glycol (PEG 8000).
Further concentrations of phage was made in order to yield a suitable working suspension for
protein profiling, genomic digestion, and DNA extraction. This was performed by precipitation

118 with PEG 8000 (23). Briefly, 200 ml of exponential phase indicator bacteria were infected with 119 phage stock at MOI 0.01 for three hours before 1 M NaCI was added during continuous mixing at 4°C for one hour before any unlysed bacteria and cell debris were removed by centrifugation 120 (5000 xg). To precipitate phage particles, 10% PEG 8000 w/v was gradually added with 121 continuous mixing and left overnight at 4°C before centrifugation at 11,000 xg for 20 min to 122 123 sediment precipitated phage. The resulting pellets were carefully re-suspended overnight with 1 124 ml of SM buffer and stored at 4°C.

Heat-inactivation of phage. A phage suspension at 1x10¹¹ PFU/ml was treated for 45 mins at 125 80°C- which we established inactivated the virus with a 7-log -fold drop in PFU/ml. 126

127 **One-step growth.** We used the procedure described by (24) with some modifications. Briefly, 5 128 ml of exponentially growing cultures of E. faecalis OS16 were infected with SHEF2 phage at 129 MOI of 0.1. After 5 min of phage adsorption, bacteria were diluted 200 times (to prevent further 130 infection), and incubated at 37°C. Two samples were taken every 5 min with one used to 131 enumerate free-phages in solution; the second was treated with 1% (v/v) chloroform to release 132 intracellular phage and was used to enumerate total phage number. Phage titers were 133 determined as described previously and plaques counted on double layer agar plates.

134 Analysis of phage proteins. To define the major proteins present in the bacteriophage SHEF2, 4, 5, 6, and 7, SDS-polyacrylamide gel electrophoresis (PAGE) was performed. A PEG 135 136 8000 concentrated phage stock was mixed with an equal volume of chloroform in order to 137 release the phage particles before vortexing until an emulsion formed and centrifuged at 10,000 xq for 10 min, 50 µl from the upper laver (10¹¹-10¹³ PFU/ml) was then mixed with 50 µl of SDS-138 PAGE loading buffer and heated at 95°C for 7 min. 10 µl of lysate was loaded directly onto 4-139 140 12% NuPAGE® Bis-Tris precast gels (Thermo fisher scientific, UK) and electrophoresed for 60

6

 \triangleleft

min. Gels were stained with InstantBlue (Expaedeon) and imaged using a gel documentation
system (Image scanner power look1120 USG, Amersham Bioscience).

143 Mass spectrometry

144 In gel digestion. Gel bands were excised and diced into 1 mm pieces prior to destaining using 200 mM ammonium bicarbonate (NH4HCO3), 40% v/v acetonitrile (ACN). Samples were 145 reduced and alkylated by sequential addition of 10 mM dithiothreitol, 50 mM NH₄HCO₃, 50°C for 146 147 30 min and 55 mM iodoacetamide, 20 min at room temperature in the dark. Gel pieces were 148 dried using ACN, before rehydration into a 10 ng/µl solution of trypsin prepared in 50 mM 149 NH₄HCO₃. Samples were digested overnight at 37°C. Peptides in the supernatant were 150 harvested, and combined with peptides obtained by extraction of the gel pieces using 97% 151 ACN, 0.1% (v/v) Formic acid (FA). Peptides were dried by centrifugal evaporation using a 152 Scanvac vacuum centrifuge (Labogene, Denmark) connected to a Vacuubrand Vacuum Pump 153 (Vacuubrand, Germany) before resuspension in 3% v/v ACN, 0.1% trifluoroacetic acid (TFA).

154 LC-MS/MS. Peptides were analyzed by nano-HPLC (UltiMate 3000 HPLC System, Thermo, 155 Hemel Hempstead, UK) coupled to an amaZon ETD MS ion trap spectrometer (Bruker 156 Daltonics, Bremen, Germany) using nano-ESI spray. The nano-HPLC system and the ion trap 157 spectrometer were controlled using the Bruker Compass HyStar v3.2-SR2 software. The liquid 158 chromatography system comprised a reversed-phase precolumn (LC Packings, Dionex) for 159 sample desalting and PepMap 100 reversed-phase C18 column, 75 µm x 15 cm (Thermo, 160 Hemel Hempstead, UK), for peptide fractionation. The flow rate for precolumn loading was 30 161 µL/min of loading buffer (97% v/v ACN, 0.1% (v/v) TFA). Peptides were analysed at a flow rate 162 of 300 nL/min and separated by gradient elution using Buffer A (3% v/v ACN, 0.1% (v/v) FA) 163 and Buffer B (97% ACN, 0.1% FA (v/v)): 4% B (0-5 min), 5-38% B (5-65 min), 38-90% B (65-68 164 min), 90% B (68-73 min), followed by re-equilibration at 4% B. The electrospray was operated 165 in positive ion mode with 4500 V spray voltage and 10 psi gas pressure, 150°C dry gas. The

 \triangleleft

end plate offset of the mass spectrometer was set to -500 V and for the acquisition the standard
method Proteomics Auto MSMS.

Database searching. Protein identifications were obtained using the Mascot software platform 168 169 (MatrixScience, in house server) to perform database searching against both the EMBOSS 170 6.5.7.0, and CDS annotation for phage SHEF2 sequence (Accession Number MF678788). Contaminants such as human skin keratin and trypsin were assigned by parallel searching 171 172 against the cRAP UniProt database (116 sequences, 38,459 residues; downloaded 30 Jan 173 2015) database. A concatenated target-decoy database search strategy was also employed to 174 estimate the rate of false discovery rate. MS/MS search parameters were Search Enzyme: 175 Trypsin; Max missed cleavages: 1; Fixed modifications: Carbamidomethyl (C); Variable 176 modifications: Oxidation (M): Mass values: Monoisotopic: Protein mass: Unrestricted: Peptide 177 mass tolerance: ± 1.2 Da; Fragment mass tolerance: ± 0.6 Da; Instrument type: ESI-TRAP.

178 MLST designation of strains used. To establish the MLST (multi locus sequence type) profile 179 of each of the strains used, Genomic DNA was extracted using the Wizard Genomic DNA 180 extraction kit (Promega), followed by PCR using the primers previously described (25) The 181 purified PCR fragments were sequenced in both directions by GATC Biotech AG using the 182 same primers. Sequence type (ST) and cluster allelic profiling were determined using the 183 eBURST V3 software accessible the via Internet-accessible data-base (http://efaecalis.mlst.net/;) (26, 27). MLST designations are presented in table 3 184

Phage DNA extraction. To remove contaminating DNA and RNA from the PEG 8000 concentrated phage stocks, a 10 µg/ml DNase and RNAse solution was added and incubated at 37°C for 30 min before 100 µg/ml of proteinase K was added to degrade nucleases at 50°C for 45 min. Removal of proteins from nucleic acids was achieved by extraction with phenol: chloroform: isoamyl alcohol (25:24:1 v/v). DNA was precipitated by adding two volumes of ice

 \triangleleft

cold ethanol and incubated overnight at -20°C before DNA was pelleted at 16,000 xg for 20 min,
and washed with 70%, before DNA was dissolved in sterile milli-Q-water and stored at -20°C.
These samples were used for nucleotide sequencing and restriction fragment length polymor
sm (RFLP) analysis of phage genomes.

194 **Restriction fragment length polymor sm (RFLP) and analysis of phage genome size.** 195 Phage genomic DNA was subjected to restriction digestion with *Hind*III, *Nde*I and *Mfe*I, (New 196 England, Biolabs, UK) according to manufacturers instruction. The digested products were 197 separated by 1% ETBr-agarose gel electrophoresis to determine RFLP patterns and gels 198 visualised using an Ingenius 3 gel-doc system, (SYNGENE).

Genome sequencing of phages SHEF2, SHEF4 and SHEF5. Pure phage genomic DNA (20 199 200 µg) was sequenced by MicrobesNG on an Illumina MiSeq platform with 2 x 250 bp paired-end 201 reads before identification of the closest available reference genome using Kraken (28), and 202 reads mapped using BWA mem (29) to assess the quality of the data. Reads were trimmed 203 using Trimmomatic (30) before de novo assembly using SPAdes (31). An automated annotation 204 was performed using Prokka (32), before Mauve align software tool (33) was used to perform visual multiple comparisons while multiple sequence alignment of individual genes was 205 206 performed using Multalin (34). In addition, PHAST (PHAge Search Tool) (35) and PHASTER 207 (PHAge Search Tool Enhanced Release) (36) web servers were used for further confirmation of 208 annotated phage genomes. Conserved protein domains (where relevant) were detected using 209 Pfam (37). Complete genomes were visualized using Artemis (38) and submitted to the NCBI as 210 individual contigs with accession number MF678788, MF678789, and MF67878890 for SHEF2, 211 SHEF4, and SHEF5 respectively.

Biofilm assay on polystyrene plates. The ability of the enterococcal strains to form a biofilm
on an abiotic surface was quantified based on a previously described method (39). Briefly, *E.*

 \triangleleft

214 faecalis strains were grown overnight in BHI at 37°C. The cultures were diluted 1:40 in fresh BHI 215 medium and 1 ml of this cell suspension was used to inoculate sterile flat-bottomed 48-well polystyrene microtiter plates (Cellstar, Greiner Bio-One). Six wells per strain were inoculated 216 217 with BHI alone as negative controls. These were then incubated under stationary conditions (aerobic) at 37°C for the time indicated. For longer term biofilms, the media was changed every 218 219 24 h. Broth was then carefully drawn off from wells and 1 ml fresh broth containing 10⁸ PFU/ml 220 SHEF2 phage or BHI only controls were added before incubation for another 3 h. Wells were then gently washed three times with 1 ml of phosphate-buffered saline (PBS). The plates were 221 222 inverted on a paper towel, air-dried and stained with 1% crystal violet for 15 min. The wells were 223 washed again 3 times, and the crystal violet was solubilized in 500 µl of ethanol-acetone (80:20, v/v) and OD₅₇₀ measured using a microplate reader (Tecan infinite 200, Austria). Each assay 224 225 was performed in triplicate and repeated three times.

226 Adsorption rate experiments. The adsorption rate experiments were performed according to 227 the procedure described previously (40) with small modifications. Briefly, overnight cultures of the bacterial strains were diluted 1:100 in BHI medium. When the OD_{600} of the reference strains 228 reached 2.0, 1 ml of culture was diluted 10-fold in fresh BHI (5 x 108 CFU/ml). Phages were 229 230 added at an MOI of 1 to the diluted culture, mixed gently, and incubated at 37°C. Incubation was 231 continued for 12 min, with samples (100 µl) collected at one-min intervals and diluted 232 immediately in 900 µl cooled SM buffer. The diluted samples were centrifuged at 10000 xg (4°C) for 5 min and passed through a 0.45 µm filter. Finally, the titres of unabsorbed phages in 233 234 the supernatant were determined after serial dilution. The adsorption levels were represented by the percentage of the total number of phages: calculated as follows: [(initial phage titer / free 235 phage titer in supernatant)_/initial phage titer] x 100. 236

In vitro biofilm assay on tooth root surface. The ability of SHEF2 phage to eradicate *E. faecalis* biofilm on extracted natural root surface was quantified based on a previously described

239

 \triangleleft

Infection and Immunity

240 root slices were cross sectioned above the root bifurcation area of multi-rooted human teeth (ethical approval number STH18841) by water cooled 0.1 mm cutting saw (MEDREK 859088) 241 and were divided into two groups in 24-well microtitre plates (Cellstar, Greiner Bio-One) with 242 final equal surface area for each group. 7 day (168 h) *E. faecalis* biofilm was grown as 243 244 described previously - i.e. 24 h media changes. After that, the first group (treated) was treated with 1 ml BHI contain 10⁸ PFU/ml SHEF2 phage with BHI only used as a control (untreated) 245 before incubation for another 3 h. The root slices were transferred into 48-well microtitre plates 246 247 and washed three times with 1 ml PBS. After treatment and washing, 0.350 ml of PBS 248 containing resazurin solution at a final concentration of 1 µg/ml were added to both groups in a 48-well plate and incubated at 37°C for 20 min. 0.3 ml from each well of both groups (treated 249 250 and untreated) was transferred to 96-well microtitre plates and fluorescence was read using a 251 microplate spectrofluorometer (Tecan infinite 200 at λ_{exc} 570 nm, λ_{em} 590 nm). The reading of 252 the non-emitting dye of resazurin (treated) was subtracted from a control group that contained 253 only the resazurin dye. This assay was repeated 2 times with at least 3 samples in each group. In addition we performed a standard curve of bacteria (CFU/mI) vs resazurin (Fig S3C). 254 255 Zebrafish as in vivo model for phage treatment. Zebrafish maintenance and experimental 256 work was performed in accordance with UK Home Office regulations and UK Animals (Scientific

method using Resazurin dye change (41, 42). To produce a growth surface, 1 mm thickness

257 Procedures) Act 1986. Ethical approval was given by the University of Sheffield Local Ethical Review Panel. Wild-type (WT) inbred zebrafish larvae were obtained from The Bateson Centre, 258 259 University of Sheffield. All larvae were maintained in E3 medium at 30°C according to standard 260 protocols and monitored for up to 4 days post-fertilization (dpf). Groups of at least 20 larvae were used for each treatment condition. Tricaine-anesthetized embryos were injected 261 individually with 2 nl of E. faecalis (30,000 CFU) into the Duct of Cuvier of dechorionated 262 embryos at 30 hours post-fertilization (hpf) and larvae were incubated for 2 h before injection 263

 \triangleleft

with 2 nl of SHEF2 phage (MOI of 20, in relation to the original bacterial innoculum) or PBS. Fish health status was monitored for up to 72 hours post-infection (hpi). In parallel larvae were also injected with either PBS only, *E. faecalis* only or Phage only alongside heat-killed phage. In all cases, fish health status was monitored for up to 72 hpi. Zebrafish mortality was assessed based on the examination of the presence of a heart beat and blood circulation (43). Images of 10% formalin-fixed zebrafish larvae were captured using a fluorescence zoom microscope (Axio Zoom.V16, Zeiss) with Zen Black software.

271 Assessment of phage adhesion. Phage adsorption rates were established as described 272 earlier, with free phage particles of SHEF2 were counted at 0, 10 minutes, and 24 h post-273 infection with epaB mutants cells and compared to control OG1RF cells. The free phage 274 particles was also counted from 24 h suspension after treatment with 1% (v/v) chloroform in 275 order to lyse all cells to release any possible trapped intracellular phage. In addition, 1 ml 276 samples from the 24 h phage-bacterial suspension was pelleted and re-suspended in ice cold 1 277 ml PBS in 0.28 M NaCl (previously shown to breakdown electrostatic interactions between 278 phage and cell wall material (23) for 10 min at 4°C. These samples were then passed though a 279 0.45 µm filter to collect phage released, and the titre of free phage in the supernatant 280 established. The phage count from the 0.28 M NaCl sample was deducted from the free phage 281 count of the control group of PBS (0.150 M NaCl) to assess how many were adsorbed and 282 released by increased NaCI. Additionally, and to exclude cell lysis caused by increasing the 283 molarity of NaCl, CFUs were assessed and compared to the control group. This experiment was 284 repeated twice in triplicate each time.

Statistical analysis. Statistical analysis was performed using t-test using Graphpad Prism v7.0
(GraphPad, La Jolla, CA) and statistical significance was assumed if p<0,05. For zebrafish
experiments, Kaplan-Meier survival curves were compared using log rank test and differences
between unhealthy groups were evaluated using One-way ANOVA.

 \triangleleft

289 Results

290 Isolation and characterisation of bacteriophages targeting *E. faecalis*

Sheffield wastewater was used as a potential source for *E. faecalis* specific bacteriophage (several samples from independent sites). Phage plaques were first identified by spotting the processed sewage solution on top-agar lawns of a range of orally isolated clinical strains of *E. faecalis* (Table 1), with plaques successfully obtained with *E. faecalis* OS16, EF2, EF3 and OMGS3919. To isolate individual phages, this procedure was repeated twice and five bacteriophages named SHEF2, 4, 5, 6, 7 were identified using a range of *E. faecalis* isolates (Figure 1)

Three distinct plaque morphologies were identified with SHEF2, 5, 6 and 7 phage forming plaques with 3-4 mm diameter surrounded by a thin area of secondary lysis of 1 mm, while SHEF4 formed 2 mm diameter central plaques surrounded by halos of larger secondary lysis (Figure 1A). When infecting the strain OG1RF, SHEF7 formed small pin hole-sized plaque of 1 mm diameter without distinct secondary lysis while it forms large plaques with OMGS3919 (Figure 1A).

Negative staining transmission electron microscopy of purified phages revealed that all bacteriophages had polyhedral head-shapes and non-contractile long tails ranging from 200 to 250 nm and polyhedral heads (Figure 1B) with diameters between 41-46 nm (Table 2). According to the guidelines of the International Committee on Taxonomy of Viruses (ICTV, 2005), the SHEF bacteriophages were classified as belonging to the family *Siphoviridae* (order *Caudovirales*) based upon their tail morphology (44).

310 Molecular characterisation of isolated phages

311 Digestion of phage DNA with restriction enzymes and DNase I indicated that all isolated 312 phages were double stranded DNA viruses. Restriction fragment length polymorphism (RFLP) tests were performed on phage chromosomal DNAs (Figure 1C). The restriction profiles of 313 314 SHEF2 and 6 were very similar, whilst all the others were different. From the RFLP analyses, the five phage genome sizes were estimated to be in the range of 39-43 kbp. Next, we analysed 315 316 purified phage particles by SDS-PAGE (Figure 1D). Distinct protein profiles suggested five 317 separate phage were isolated. All samples revealed a prominent band at 36 kDA (Figure 1D), which Mass Spectrometry confirmed as the phage major capsid protein for SHEF2 (Figure 2, 318 319 SHEF2 07). While it is likely that this band is the head protein in all cases, we do not have MS 320 data to confirm this. In short, we successfully confirmed the isolation of five separate E. faecalis 321 bacteriophage of the family Siphoviridae.

322 Determination of host-range

323 The host-range of the phages isolated was studied using both spot and SAO methods at 324 MOI of 0.1 to detect visible plaques. All five SHEF bacteriophages were specific to E. faecalis 325 as none were capable of producing visible plaques using E. faecium (data not shown). Host-326 range tests showed that all phage have distinct strain specificity preferences, with SHEF2 displaying the broadest host-range with capacity to lyse 9 out of 13 E. faecalis indicator strains 327 328 tested, followed by SHEF6 and 7. SHEF5 and 4 possess the narrowest host-range, lysing only 3 329 and 2 strains, respectively. Despite the similarities between SHEF2 and 6 at the genomic level, 330 their host-range is not identical, indicating they are distinct phage. No relationship between 331 host-range and MLST type was found.

332 Genome organization of SHEF2, 4 and 5.

333 The genomes of phages SHEF2, 4 and 5 revealed similar sizes of 41.7, 41.1, and 41.6 334 kbp respectively and appeared to be organised into two halves, transcribed in opposite directions (Figure 2A). Each genome was assembled into one large contig with low read 335 mapping coverage at the 5' and 3' ends and no clear edges at the ends of the contigs, 336 suggesting circularity of terminally redundant permuted genomes. Four gene clusters 337 338 corresponding to DNA packaging, structural components, cell lysis and, regulation and 339 replication were identified (Figure 2A,B). There is little noncoding DNA between these genes, suggesting single transcripts for each set of genes. Although each phage exhibits a different 340 341 host range, a high identity was found for both DNA and primary amino acid level of between 77 342 and 94% (see Figure S1). Importantly, no putative integrase encoding genes were detected in the genome sequences, suggesting that the SHEF phages are likely to be lytic in nature. 343

344 All SHEF phages share a similar distribution pattern for DNA packaging and head 345 morphogenesis genes (Figure 2A, orange), and are upstream of the terminase (45, 46). The 346 predicted head module (Figure 2A, cyan) harbours genes encoding portal proteins (for genome 347 injection into host cells), prohead protease maturation, head capsid proteins and head-tail 348 adaptor proteins. These genes are followed by tail and tape-measure proteins (Figure 4A, 349 green) and a lysis module (Figure 2A, yellow) containing a putative haemolysin XhIA, putative 350 holin and endolysin genes. SHEF2 and 5 encode putative endolysins (SHEF2 21 351 andSHEF5 49) with an N-terminal Amidase 2 domain and a predicted C-terminal 352 ZoocinA TRD (pfam16775) domain. SHEF4 encodes a putative endolysin with the same N-353 terminal domain but an SH3b peptidoglycan-binding domain, indicating differing cell-wall 354 targeting mechanisms.

The replication and regulation module are also clustered and ordered identically, except that SHEF4 encodes for an adenine-specific methyltransferase (modification methylase *Dpn*IIB) that is absent from SHEF5. In addition, SHEF4 and 5 harboured an additional putative

 \triangleleft

Infection and Immunity

 \triangleleft

transcriptional regulator gene that is absent from SHEF2 and suggest that all three employ
slightly different modes of post-replication and DNA modification that might be key during the
infection cycle.

361 Phage tail proteins are involved in the primary recognition and adsorption to specific receptors on the bacterial cell surface (47, 48). Since SHEF2, 4 and 5 exhibit different host 362 363 ranges, we examined the amino acid sequence of the predicted tail proteins (Figure 2B). The 364 first three proteins displayed a high sequence similarity (81-100%). In contrast, the N-terminal 365 130 aa (out of 695 aa) of the fourth tail protein (SHEF2 16, 4 08 and 5 53), shares very high 366 similarity (>95%) across our phage, while the rest of the sequence was highly divergent (Figure S2A). We obtained similar results with the fifth tail protein (SHEF2 17, 4 09 and 5 52), where 367 the first 175 amino acids (out of 800 aa) encode conserved putative tail domains (TIGR01665 368 369 and pfam06605), before the rest of the protein sequence diverges (Figure S2B). We propose 370 that these two genes may be key to the host-range determination of these phage during 371 infection as has been seen for other E. faecalis phage (51) and represent alternate cell-wall 372 binding proteins and domains.

373

374 Identification of the enterococcal polysaccharide antigen as the SHEF2 receptor

375 To gain further insight into the mechanisms driving strain specificity in these phage we 376 sought to identify the receptor for SHEF2. We considered a candidate to be the prominent cell 377 surface rhamnopolysaccharide enterococcal polysaccharide antigen (EPA) (49-51). The genetic 378 locus encoding the synthesis of EPA is composed of 18 highly conserved genes (epaA-R) 379 followed by a variable region which is divergent between strains (Figure 3A) (22), and which has 380 been proposed to encode strain specific decoration of the core polysaccharide synthesised by a 381 conserved genetic region (22, 52). Disruption of epaB (strain TX5179(epaB)), a key rhamnosyl 382 transferase involved in EPA backbone synthesis, abolished infectivity of SHEF2 with infectivity

 \triangleleft

383 restored upon complementation with a plasmid containing the epaBCD operon (Figure 3B). We then tested infection of strain oatApgdAdltAsigV, characterised by Smith et al (22) that has 384 altered Peptidoglycan and Teichoic Acid production, showing that it is still sensitive to infection 385 and that these molecules are not receptors for SHEF2. 386

387 As mentioned above, the core EPA is further decorated by variable chemical modifications that modulate virulence. We next tested the infectivity of SHEF2 against mutants 388 in the epa variable region using mutants previously shown to impair EPA decorations and 389 390 virulence (22). Three of the mutants had insertions in genes encoding glycosyl transferases (OPDV 11720::Tn, OPDV_11715::Tn and OPDV_11714::Tn) and one had an insertion in an 391 epimerase gene (OPDV 11707::Tn). All variable region mutants showed a markedly reduced 392 393 infectivity by SHEF2 which was restored upon *in trans* complementation. Interestingly, the 394 OG1RF 11714 mutant was still partially infected by SHEF2, with a slightly opaque plaque observed, that was restored to a typical clear plaque by complementation (Figure 3B and S4). 395

396 Despite this lack of infection of epa mutant strains, it was still possible that binding 397 occurred but that the phage was unable to complete its full lytic cycle. To explore this possibility 398 we carried out an adsorption assay. In this assay, phage and bacteria were incubated together 399 for 24 hours to allow adsorption of phage/ or infection to proceed before the addition of 0.28 M 400 NaCl, a treatment known to interfere with electrostatic phage-bacterial interactions, but not harm 401 Enteroccocus cell viability. For strain TX5179(epaB) total phage numbers did not increase over 402 24h- again indicating lack of infection and expansion as compared to the OG1RF strain (Figure 3C). However, the NaCl treatment released 1.4x10⁵ PFU/ml of phage (51.8%, P<0.01 vs 403 404 OG1RF, 11720), reflecting weak adsorption of phage that do not enter a lytic life cycle but are 405 still viable. Adsorption without population increase was also observed with the 406 OPDV 11720::Tn2.5 however less phage were recovered after 0.28M NaCl treatment (1.75%, 407 P<0.01 vs OG1RF, epaB) indicating a stronger interaction with more phage left adsorbed after

Accepted Manuscript Posted Online

Infection and Immunity

 \triangleleft

408 NaCl treatment. To exclude the possibility that phage progeny were trapped inside the host cells 409 that could not lyse the host membrane and escape, cell suspensions were treated with chloroform, with no further release of viable phage particles. Finally, to examine qualitatively 410 that the released phage is bound to the cells, electron microscopy was performed on OG1RF, 411 TX5179(epaB) and OPDV_11720::Tn2.5 cells cultured with phage. Indeed phage could be 412 413 observed on all these strains (Fig. 3D) indicating that cell surface binding is still occurring in these mutants and that the core and variable EPA are both bound by phage SHEF2. Like others 414 (51) we observed rounded cell morphology in TX5179(epaB) (Fig. 3D), and also with the 415 416 OPDV_11720::Tn2.5 strain.

417 Infection parameters and strain preference of SHEF2

We further characterised the host range and infection characteristics of bacteriophage 418 SHEF2. As shown in Figure S5A strain OS16 (alongside ER3/2s and EF54) was highly sensitive 419 to SHEF2, as assessed by time course infection experiments, with cultures lysing within the first 420 421 60 minutes, compared to strains such as OMGS3197, 3919 or 3198 which lyse in mid (2h)- and 422 V583 in late (3h)- exponential phase, respectively (Fig. S5). As a result and since it is an orally 423 isolated clinical strain, we used strain OS16 to perform a one-step growth experiment to 424 establish the eclipse period (average time to produce the first mature intracellular phage), latent 425 period (average time to cell lysis) and burst size (the average number of phage released at cell 426 lysis), which showed SHEF2 as a highly efficient *E. faecalis* targeting phage with an eclipse 427 period of only 10 min, a latent period of only 30 min (Figure 4A), and a burst size of 9.3 PFU for 428 this strain. The plateau phase was reached after 75 min, following a 45 min burst period. Next, 429 we examined adsorption parameters of this phage with the E. faecalis strain OS16, and found 430 that saturation of adsorption was reached after 10 min (Figure 4B). This adsorption is illustrated 431 in Figure 4C where a TEM taken of cells at 30 min post infection illustrates attached phage 432 attached to the cell surface.

 \triangleleft

433

434 Ability of SHEF2 to clear *E. faecalis* biofilms

435 Given that most bacteria in nature and in clinical infections reside in biofilms (53, 54) we tested 436 the ability of SHEF2 to eradicate E. faecalis biofilms in vitro on inert polystyrene surfaces, 437 using a range of strains. As seen in Figure 5A, we tested the phage against 24h preformed 438 biofilms, using heat-killed phage as a negative control, and showed phage-dependent 439 clearance- to varying degrees (3-10-fold), of all sensitive strains (EF54, OS16, OG1RF), while we observed no clearance for strains EF3 and OG1RF-epaB, which were insensitive to phage 440 infection in plate based and broth based assays. In addition, we tested clearance of biofilms of 441 442 strains EF54 and OS16, as well as a mixed strain biofilm that had been preformed for 6-days (FigS3 A,B), again showing clearance of biofilm in a phage dependent manner. 443

We next tested the efficacy of phage SHEF2 to eradicate biofilms on natural tooth root 444 surfaces by growing EF54 biofilms for 168 h before adding SHEF2 (1x10⁸ PFU/mI) for 3 h, and 445 achieving a significant reduction in bacterial numbers, as indicated by reduction in detectable 446 metabolic activity (Figure 5B, P<0.0001) (resazurin assay) to approximately 7x10³ bacteria in 447 total estimated using standard curves of Emission ((@590nm) vs CFU/ml Fig. S3C), from an 448 original input of over 1x10⁶ (N.B. we were unable to do this on more strains due to limitations of 449 available tooth slices and ethics restrictions). We also observed, qualitatively, a drastic 450 451 decrease in bacterial material via reduction in visible bacterial biomass visualised as the dark material in this image using stereomicroscopy and light microscopy (Figure 5C). 452

453 Phage treatment evaluation in a zebrafish model of infection

454 Next, we performed systemic infection studies using an established zebrafish model of 455 infection (55) and the clinical strain OS16. Zebrafish embryos were infected with *E. faecalis* for

two hours before injecting with SHEF2 or a heat-killed sample of SHEF2 at a multiplicity of 456 457 Infection (MOI) of 20 (with respect to the *E. faecalis* inoculum), alongside virus only controls. Fish mortality and health status was then monitored up to 72 hpi. E. faecalis OS16 caused a 458 time-dependent lethality that was significantly higher (p<0,0001) than PBS control or phage 459 alone (Figure 6A, B). Whilst injection with heat-killed (HK) SHEF2 phage post-infection with 460 461 strain OS16 did not improve mortality rates of the zebrafish (73% dead, identical to OS16 only), 462 injection of live SHEF2 resulted in only 16% death (and thus 84% survival) (p<0.0001, vs OS16 only). Of note, at fish injected with phage only (SHEF2(LIVE)) or inactivated phage (HK-463 464 SHEF2) alone were healthy. Morphology and overall health status of the fish was also 465 466 467 468

monitored, showing that viable phage allowed recovery from OS16 infection while the HK-SHEF2 did not (Figure 6B). We also infected embryos with strain EF3, which is not sensitive to SHEF2 infection (Table 2), but still displayed the ability to cause mortality in embryos by 72 hpi (90%, p<0,0001) compared to PBS, live or killed phage alone injected fish (Fig.6B,C). Significantly, neither viable or heat-killed SHEF2 phage caused an improvement in survival 469 470 when injected alongside strain EF3 with 81.13 (± 5.46%) and 80.13 (± 1.27%) death respectively. In all experiments, the embryos infected with E. faecalis-only displayed a lack of 471 circulation, yolk sac and eye abnormalities, alongside pericardiac oedema and spine curvature 472 (Fig. 6D, shown for OS16). In contrast, the majority of phage-treated zebrafish remained healthy 473 474 throughout the experiment with health status comparable to phage only and PBS-injected 475 controls (Figure 6B).

476

477 Discussion

478 In this paper we report the isolation of 5 lytic phage isolated from wastewater using a 479 range of oral and non-oral E. faecalis strains. Surprisingly, we were unable to isolate phage

 \triangleleft

from oral samples against our strains, even though we could visualise phage in concentrated saliva (not shown) even though metagenomic evidence from others that the oral cavity is rich in bacteriophage DNA (56).

All the phage described in this study (SHEF2, 4, 5, 6 and 7) belonged to the family Siphoviridae, a family of phage previously found to target *E. faecalis*, (16, 19, 57, 58), alongside members of the *Myoviridae* (18, 20, 21).

486 Our isolated phage (SHEF2, 4, 5, 6 and 7) possessed differing host ranges, with SHEF2 487 having the broadest. After genome sequencing we found strong similarity between the genome 488 sequences of SHEF2, 4 and 5 (SHEF2 is 92-94% identical to SHEF4 and 5 respectively) but significant divergence in the putative tail gene locus genes (SHEF2_16, _17, SHEF4_08, _09, 489 and SHEF5 53, 52) with evidence of conserved N-terminal domains but different putative 490 491 bacterial surface receptor binding domains in the C-terminus of these proteins. Similar observations have been made in various species including Lactococcus lactis phage (59, 60) 492 493 and Streptococcus thermo lus phage DT1 where interchange of the C-terminal domain of 494 ORF18 with that of another phage (MD4) altered host-range specificity (61). We suggest that tail 495 module genes four and five encode host-range specificity determining tail proteins that contain 496 potentially novel E. faecalis surface binding domains. These findings will open the way for 497 further investigation of phage host specificity and adhesion of Gram-positive bacteria.

To probe the cell surface receptor for the SHEF2 phage we showed that it was unable to productively infect insertion mutants with altered core EPA (*epaB*) or EPA decoration genes. All decoration mutants showed reduction in infectivity except for *OPDV_11714::Tn2.14*. The partial infectivity of *OPDV_11714::Tn2.14* is in line with previous observations showing that mutation of this gene has only a small impact on EPA decoration (22). For both the *epaB* and _11720 (decoration) strains the lack of infectivity is despite the phage retaining the ability to adsorb to

 \triangleleft

the bacterial cell surface. Interestingly there is a discrepancy between the amount of phage recovered from the cell surface of TX5179 and *OPDV_11720::Tn2.5* with more phage still bound to the decoration deficient mutant. This data suggests that SHEF2 likely binds to both the core polysaccharide and decoration residues, and needs both for infection. In a similar manner, this is also the case for several well-characterised bacteriophage, e.g. *E.coli* T4 phage (which requires LPS and OmpC binding) (62) or *S. aureus* phage 3C that requires teichoic and peptidoglycan for irreversible binding (47, 63).

511 For phages infecting Gram-positive organisms, the injection of viral DNA requires 512 crossing the peptidoglycan layer and interaction with the cell membrane. This process has been 513 studied in L. lactis phages that bind to rhamnose moleties of the cell wall before engaging the 514 plasma membrane of the host (64-66). This process often employs phage encoded 515 glycosidases, or lysozyme like enzymes (47), with all the sequenced SHEF phage also 516 encoding a tail protein with putative lyzosyme domain (SHEF2 15, SHEF4 07 and 517 SHEF5 54). Evidence for two-stage adsorption and infection of E. faecalis exists in the case of 518 E. faecalis and phage VPE25 infection, where a plasma membrane protein (EF0858) seemed to 519 be required for lytic infection (and hence DNA injection) but not phage adsorption to the cell 520 surface receptor (67). We therefore postulate here that the EPA and its variant decoration is 521 required for productive binding of SHEF2 to the cell surface of E. faecalis with EPA and an unknown molecule acting as co-receptor for this phage. Based on the evidence in the literature 522 (68, 69) that the Epa PS is not detectable on the outer surface of E. faecalis it is tempting to 523 524 speculate that SHEF2 initially binds first to an outer cell surface PS followed by EPA, but we 525 have no evidence for this. Overall, further tests are required to establish the primary receptor of SHEF2 interaction, potentially by producing recombinant versions of the tail protein domains 526 and investigating their sugar binding properties. Such studies will open new insight into possible 527

resistance mechanisms for phage infection but also new targets for anti-infectives against *E*.
 faecalis or strain specific diagnostics based on cell wall component binding capability.

530 The capacity to form biofilms is critical for *E. faecalis* virulence, providing resistance to 531 antibiotics and allowing infections to persist. Studies have shown a strong association between 532 virulence and biofilm formation with 15-80% of clinical isolates being classified as strong biofilm formers (70-72) In addition, 75% of enterococcal infections in humans (bloodstream, urinary 533 tract, and wound infections) are caused by E. faecalis (2). We showed that SHEF2 can 534 535 significantly reduce biofilm formation of a range of sensitive E. faecalis strains (3-10-fold) that 536 were pre-formed (24h) on polystyrene surfaces (mimicking catheters for example) as well as on 537 a novel in vitro tooth-cross-section biofilm model (i.e. human tooth cross sections). We believe 538 this to be a strong indication that phage therapy based on SHEF2 and potentially our other 539 phage might be useful for eradication of root-canal infections. In support of our data an ex-vivo 540 root canal model, developed by Khalifa et al., 2015, was also significantly cleared of bacteria by 541 phage (20). The use of bacteriophages therefore appears to be a promising strategy to reduce 542 the biofilm bacterial load associated with E. faecalis infections, providing a potential adjunctive 543 therapy for root canal infection that has failed to respond to conventional treatment. Other oral 544 infections such as periodontal disease, which is a complex mixed species infection would 545 require phages targeting other oral pathogenic bacteria. However, based on reports of phage targetting Aggregatibacter actinomycetemcomitans (73), and Fusobacterium spp. (74, 75), 546 alongside several Streptococcus (76),, Veilionella (77) and Neisseria spp (78) in the literature 547 548 this may be a feasible future approach.

In addition to oral infections, *E. faecalis* is a well-known cause of septicaemia (79) with reports showing that oral bacteria can enter the bloodstream and disseminate systemically, contributing to infections such as endocarditis and rheumatoid arthritis (79, 80). We tested the therapeutic potential of the phages we isolated in a well-established *in vivo* zebrafish embryo

553 systemic infection model. We showed, for the first time, that systemic phage treatment after 554 infection with *E. faecalis*, dramatically decreased the mortality of zebrafish embryos and greatly improved their health during infection, indicating the potential of this phage in treating systemic 555 E. faecalis infections. It is important to note that neither the phage or bacterial components 556 released upon lysis displayed toxicity toward the embryo further demonstrating potential for safe 557 558 use of phage systemically. The zebrafish infection model also served extremely well as a 559 system to test the efficacy of phage against systemic bacteria and act as powerful tool for 560 monitoring the dynamics of infection and phage clearance of infection that can be monitored in real-time (81). Given the effectiveness of the phages described in killing planktonic and biofilm 561 562 associated E. faecalis, as well as in a systemic infection model their therapeutic use could be 563 extended to other infection types such as sepsis, wound infections or urinary tract infections.

564 It is well documented that bacteria can gain resistance to bacteriophages, and indeed 565 resistance to E. faecalis phage has been previously reported (82). However, we did not isolate 566 resistant strains during our experiments, but cannot rule out that this could occur and consider 567 that the use of a cocktail of phage targeting different cellular receptors would be the best mode 568 to reduce and combat resistance arising. Of note here is that resistance arising to at least 569 phage SHEF2 for example, would require alterations in the EPA core or variable moieties, an 570 alteration that would likely result in reduced virulence (22). It is worth noting here that many of 571 the strains that were sensitive to our small panel of phage in this study were resistant to a range of antibiotics, including vancomycin (e.g., strain V583), and illustrating that phage have the 572 573 potential to be used as an adjunct or alternative treatment in infections caused by antibiotic 574 resistant strains of important human pathogens.

575 In conclusion, this study highlights isolation of phage targeting *E. faecalis* strains 576 targeting a major virulence determinant of this strain (EPA), and establishes their potential use 577 in treating biofilm infections by testing them in two clinically relevant model infection systems.

 \triangleleft

578 Our work thus strenghtens the possibility of developing phage as therapeutics to combat hard-579 to-treat oral, topical and systemic infections.

580

581 ACKNOWLEDGMENTS

MA was funded by a scholarship from the Iraqi High commission. We thank Barbara 582 Murray, Gunnar Dahlen and Wim Crielaard for E. faecalis strains used in this work. We also 583 584 thank Chris Hill at the Electron Microscopy unit for assistance and training for the TEM work and 585 MicrobesNG (<u>http://www.microbesng.uk</u>) for sequencing. We also thank Prof. Nic Martin, 586 Sheffield, for help in designing and providing the material for the tooth cross-sectional model. 587 EC was funded by a EPSRC Grand Challenge Twenty65 grant (EP/N010124/1). RES was funded by a Biotechnology and Biological Sciences Research Council studentship 588 (grant BB/M011151/1). 589

590

591

592

593

594

25

595 **REFERENCES**:

596

- Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004.
 Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clinical infectious diseases 39:309-317.
- 600 2. Gilmore MS, Lebreton F, van Schaik W. 2013. Genomic transition of enterococci from 601 gut commensals to leading causes of multidrug-resistant hospital infection in the 602 antibiotic era. Current opinion in microbiology 16:10-16.
- Paulsen IT, Banerjei L, Myers G, Nelson K, Seshadri R, Read TD, Fouts DE, Eisen JA,
 Gill SR, Heidelberg J. 2003. Role of mobile DNA in the evolution of vancomycin-resistant
 Enterococcus faecalis. Science 299:2071-2074.
- Polidori M, Nuccorini A, Tascini C, Gemignani G, Iapoce R, Leonildi A, Tagliaferri E,
 Menichetti F. 2011. Vancomycin-resistant *Enterococcus faecium* (VRE) bacteremia in
 infective endocarditis successfully treated with combination daptomycin and tigecycline.
 Journal of chemotherapy (Florence, Italy) 23:240.
- 5. Love R. 2001. *Enterococcus faecalis*-a mechanism for its role in endodontic failure.
 International endodontic journal 34:399-405.
- 6. Gopikrishna V, Kandaswamy D, Jeyavel RK. 2006. Comparative evaluation of the
 antimicrobial efficacy of five endodontic root canal sealers against *Enterococcus faecalis*and *Candida albicans*. Journal of Conservative Dentistry 9:2.
- Abdullah M, Ng YL, Gulabivala K, Moles DR, Spratt DA. 2005. Susceptibilities of two
 Enterococcus faecalis phenotypes to root canal medications. J Endod 31:30-6.
- Figdor D, Davies J, Sundqvist G. 2003. Starvation survival, growth and recovery of
 Enterococcus faecalis in human serum. Oral microbiology and immunology 18:234-239.

 \triangleleft

Mohamed JA, Huang W, Nallapareddy SR, Teng F, Murray BE. 2004. Influence of origin
of isolates, especially endocarditis isolates, and various genes on biofilm formation by *Enterococcus faecalis*. Infection and immunity 72:3658-3663.

Leclercq R. 1997. Enterococci acquire new kinds of resistance. Clinical Infectious
Diseases 24:S80-S84.

- Hunt C. 1998. The emergence of enterococci as a cause of nosocomial infection. British
 journal of biomedical science 55:149.
- Rose T, Verbeken G, De Vos D, Merabishvili M, Vaneechoutte M, Lavigne R, Jennes S,
 Zizi M, Pirnay JP. 2014. Experimental phage therapy of burn wound infection: difficult
 first steps. International journal of burns and trauma 4:66-73.
- Rhoads D, Wolcott R, Kuskowski M, Wolcott B, Ward L, Sulakvelidze A. 2009.
 Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial.
 Journal of wound care 18.
- Wright A, Hawkins C, Änggård E, Harper D. 2009. A controlled clinical trial of a
 therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant *Pseudomonas aeruginosa*; a preliminary report of efficacy. Clinical otolaryngology
 34:349-357.
- Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K,
 Gilmour KC, Soothill J, Jacobs-Sera D, Schooley RT, Hatfull GF, Spencer H. 2019.
 Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant
 Mycobacterium abscessus. Nat Med 25:730-733.
- Son J, Jun S, Kim E, Park J, Paik H, Yoon S, Kang S, Choi YJ. 2010. Complete genome
 sequence of a newly isolated lytic bacteriophage, EFAP-1 of *Enterococcus faecalis*, and
 antibacterial activity of its endolysin EFAL-1. Journal of applied microbiology 108:17691779.

M

Infection and Immunity

Fard RMN, Barton MD, Heuzenroeder MW. 2010. Novel bacteriophages in
 Enterococcus spp. Current microbiology 60:400-406.

Uchiyama J, Rashel M, Maeda Y, Takemura I, Sugihara S, Akechi K, Muraoka A,
Wakiguchi H, Matsuzaki S. 2008. Isolation and characterization of a novel *Enterococcus faecalis* bacteriophage φEF24C as a therapeutic candidate. FEMS microbiology letters
278:200-206.

Li X, Ding P, Han C, Fan H, Wang Y, Mi Z, Feng F, Tong Y. 2014. Genome analysis of
 Enterococcus faecalis bacteriophage IME-EF3 harboring a putative metallo-beta lactamase gene. Virus genes 49:145-151.

Khalifa L, Brosh Y, Gelman D, Coppenhagen-Glazer S, Beyth S, Poradosu-Cohen R,
Que Y-A, Beyth N, Hazan R. 2015. Targeting *Enterococcus faecalis* biofilms with phage
therapy. Applied and environmental microbiology 81:2696-2705.

Khalifa L, Coppenhagen-Glazer S, Shlezinger M, Kott-Gutkowski M, Adini O, Beyth N,
Hazan R. 2015. Complete genome sequence of *Enterococcus* bacteriophage EFLK1.
Genome announcements 3:e01308-15.

Smith RE, Salamaga B, Szkuta P, Hajdamowicz N, Prajsnar TK, Bulmer GS, Fontaine T,
Kolodziejczyk J, Herry JM, Hounslow AM, Williamson MP, Serror P, Mesnage S. 2019.
Decoration of the enterococcal polysaccharide antigen EPA is essential for virulence,
cell surface charge and interaction with effectors of the innate immune system. PLoS
Pathog 15:e1007730.

Yamamoto KR, Alberts BM, Benzinger R, Lawhorne L, Treiber G. 1970. Rapid
bacteriophage sedimentation in the presence of polyethylene glycol and its application to
large-scale virus purification. Virology 40:734-744.

667 24. Carlson K, Miller E. 1994. Single-step growth. Molecular biology of bacteriophage 4:434668 437.

28

 \triangleleft

Jamet E, Akary E, Poisson MA, Chamba JF, Bertrand X, Serror P. 2012. Prevalence and 25. characterization of antibiotic resistant Enterococcus faecalis in French cheeses. Food Microbiol 31:191-8.

Ruiz-Garbajosa P, Bonten MJ, Robinson DA, Top J, Nallapareddy SR, Torres C, Coque 26. 672 TM, Canton R, Baquero F, Murray BE, del Campo R, Willems RJ. 2006. Multilocus 673 674 sequence typing scheme for Enterococcus faecalis reveals hospital-adapted genetic complexes in a background of high rates of recombination. J Clin Microbiol 44:2220-8. 675

Feil EJ, Li BC, Aanensen DM, Hanage WP, Spratt BG. 2004. eBURST: inferring patterns 676 27. 677 of evolutionary descent among clusters of related bacterial genotypes from multilocus 678 sequence typing data. J Bacteriol 186:1518-30.

28. Wood DE, Salzberg SL. 2014. Kraken: ultrafast metagenomic sequence classification 679 680 using exact alignments. Genome biology 15:R46.

29. Li H. 2013. Aligning sequence reads, clone sequences and assembly contigs with BWA-681 682 MEM. arXiv preprint arXiv:13033997.

Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina 683 30. 684 sequence data. Bioinformatics:btu170.

31. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, 685 Nikolenko SI, Pham S, Prjibelski AD. 2012. SPAdes: a new genome assembly algorithm 686 and its applications to single-cell sequencing. Journal of computational biology 19:455-687 688 477.

689 32. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics:btu153.

Darling AC, Mau B, Blattner FR, Perna NT. 2004. Mauve: multiple alignment of 690 33. conserved genomic sequence with rearrangements. Genome research 14:1394-1403. 691

34. 692 Corpet F. 1988. Multiple sequence alignment with hierarchical clustering. Nucleic acids 693 research 16:10881-10890.

35. Zhou Y, Liang Y, Lynch KH, Dennis JJ, Wishart DS. 2011. PHAST: a fast phage search
tool. Nucleic acids research:gkr485.

Arndt D, Grant JR, Marcu A, Sajed T, Pon A, Liang Y, Wishart DS. 2016. PHASTER: a
better, faster version of the PHAST phage search tool. Nucleic acids research 44:W16W21.

Sonnhammer EL, Eddy SR, Durbin R. 1997. Pfam: a comprehensive database of protein
domain families based on seed alignments. Proteins-Structure Function and Genetics
28:405-420.

Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, Rajandream M-A, Barrell B. 2000.
Artemis: sequence visualization and annotation. Bioinformatics 16:944-945.

39. O'Toole GA, Kolter R. 1998. Initiation of biofilm formation in *Pseudomonas fluorescens*WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis. Mol
Microbiol 28:449-61.

- Yoon H, Yun J, Lim J-A, Roh E, Jung K-S, Chang Y, Ryu S, Heu S. 2013.
 Characterization and genomic analysis of two *Staphylococcus aureus* bacteriophages
 isolated from poultry/livestock farms. Journal of General Virology 94:2569-2576.
- Vision J, Wilson I, Orton T, Pognan F. 2000. Investigation of the Alamar Blue
 (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. European
 Journal of Biochemistry 267:5421-5426.
- Perrot S, Dutertre-Catella H, Martin C, Rat P, Warnet J-M. 2003. Resazurin metabolism
 assay is a new sensitive alternative test in isolated pig cornea. Toxicological sciences
 72:122-129.
- 43. Widziolek M, Prajsnar TK, Tazzyman S, Stafford GP, Potempa J, Murdoch C. 2016.
 Zebrafish as a new model to study effects of periodontal pathogens on cardiovascular
 diseases. Scientific reports 6:36023.

M

Infection and Immunity

Ackermann H-W. 2007. 5500 Phages examined in the electron microscope. Archives of
virology 152:227-243.

721 45. Fujisawa H, Morita M. 1997. Phage DNA packaging. Genes to Cells 2:537-545.

Sun S, Gao S, Kondabagil K, Xiang Y, Rossmann MG, Rao VB. 2012. Structure and
function of the small terminase component of the DNA packaging machine in T4-like
bacteriophages. Proceedings of the National Academy of Sciences 109:817-822.

- 725 47. Rakhuba D, Kolomiets E, Dey ES, Novik G. 2010. Bacteriophage receptors,
 726 mechanisms of phage adsorption and penetration into host cell. Pol J Microbiol 59:145727 155.
- 48. Chapot-Chartier M-P. 2014. Interactions of the cell-wall glycopolymers of lactic acid
 bacteria with their bacteriophages. Frontiers in microbiology 5:236.
- Xu Y, Murray BE, Weinstock GM. 1998. A cluster of genes involved in polysaccharide
 biosynthesis from *Enterococcus faecalis* OG1RF. Infection and immunity 66:4313-4323.
- Hancock LE, Shepard BD, Gilmore MS. 2003. Molecular analysis of the *Enterococcus faecalis* serotype 2 polysaccharide determinant. Journal of bacteriology 185:4393-4401.
- Teng F, Singh KV, Bourgogne A, Zeng J, Murray BE. 2009. Further characterization of
 the *epa* gene cluster and Epa polysaccharides of *Enterococcus faecalis*. Infection and
 immunity 77:3759-3767.
- 737 52. Rigottier-Gois L, Madec C, Navickas A, Matos RC, Akary-Lepage E, Mistou MY, Serror
 738 P. 2015. The surface rhamnopolysaccharide epa of Enterococcus faecalis is a key
 739 determinant of intestinal colonization. J Infect Dis 211:62-71.
- Final Stoodley L, Costerton JW, Stoodley P. 2004. Bacterial biofilms: from the natural
 environment to infectious diseases. Nature reviews microbiology 2:95-108.
- 742 54. Høiby N, Ciofu O, Johansen HK, Song Z-j, Moser C, Jensen PØ, Molin S, Givskov M,
 743 Tolker-Nielsen T, Bjarnsholt T. 2011. The clinical impact of bacterial biofilms.
 744 International journal of oral science 3:55.

55. Prajsnar TK, Renshaw SA, Ogryzko NV, Foster SJ, Serror P, Mesnage S. 2013.
Zebrafish as a novel vertebrate model to dissect enterococcal pathogenesis. Infection and immunity 81:4271-4279.

56. Ly M, Abeles SR, Boehm TK, Robles-Sikisaka R, Naidu M, Santiago-Rodriguez T, Pride
DT. 2014. Altered oral viral ecology in association with periodontal disease. MBio
5:e01133-14.

Fard RMN, Barton MD, Arthur JL, Heuzenroeder MW. 2010. Whole-genome sequencing
and gene mapping of a newly isolated lytic enterococcal bacteriophage EFRM31.
Archives of virology 155:1887-1891.

58. Zhang W, Mi Z, Yin X, Fan H, An X, Zhang Z, Chen J, Tong Y. 2013. Characterization of
Enterococcus faecalis phage IME-EF1 and its endolysin. PLoS One 8:e80435.

59. Stuer-Lauridsen B, Janzen T, Schnabl J, Johansen E. 2003. Identification of the host
 determinant of two prolate-headed phages infecting *Lactococcus lactis*. Virology 309:10 17.

Lubbers MW, Waterfield NR, Beresford T, Le Page R, Jarvis AW. 1995. Sequencing and
analysis of the prolate-headed lactococcal bacteriophage c2 genome and identification
of the structural genes. Applied and environmental microbiology 61:4348-4356.

762 61. Duplessis M, Moineau S. 2001. Identification of a genetic determinant responsible for
763 host specificity in *Streptococcus thermophilus* bacteriophages. Molecular microbiology
764 41:325-336.

765 62. Yu F, Mizushima S. 1982. Roles of lipopolysaccharide and outer membrane protein
766 OmpC of Escherichia coli K-12 in the receptor function for bacteriophage T4. Journal of
767 bacteriology 151:718-722.

Coyette J, Ghuysen JM. 1968. Structure of the cell wall of *Staphylococcus aureus*. IX.
 Teichoic acid and phage adsorption. Biochemistry 7:2385-2389.

Accepted

M

Infection and Immunity

Geller BL, Ivey RG, Trempy JE, Hettinger-Smith B. 1993. Cloning of a chromosomal
gene required for phage infection of *Lactococcus lactis* subsp. *lactis* C2. Journal of
bacteriology 175:5510-5519.

Monteville MR, Ardestani B, Geller BL. 1994. *Lactococcal* bacteriophages require a host
cell wall carbohydrate and a plasma membrane protein for adsorption and ejection of
DNA. Applied and environmental microbiology 60:3204-3211.

66. Babu K, Spence W, Monteville M, Geller B. 1994. Characterization of a cloned gene
(pip) from *lactococcus lactis* required for phage infection. Developments in biological
standardization 85:569-575.

Duerkop BA, Huo W, Bhardwaj P, Palmer KL, Hooper LV. 2016. Molecular basis for lytic
bacteriophage resistance in enterococci. MBio 7:e01304-16.

781 68. Xu Y, Singh KV, Qin X, Murray BE, Weinstock GM. 2000. Analysis of a gene cluster of
782 *Enterococcus faecalis* involved in polysaccharide biosynthesis. Infection and immunity
783 68:815-823.

Hancock LE, Gilmore MS. 2002. The capsular polysaccharide of *Enterococcus faecalis*and its relationship to other polysaccharides in the cell wall. Proceedings of the National
Academy of Sciences 99:1574-1579.

787 70. Baldassarri L, Cecchini R, Bertuccini L, Ammendolia MG, Iosi F, Arciola CR, Montanaro
788 L, Di Rosa R, Gherardi G, Dicuonzo G. 2001. *Enterococcus* spp. produces slime and
789 survives in rat peritoneal macrophages. Medical microbiology and immunology 190:113790 120.

791 71. Di Rosa R, Creti R, Venditti M, D'Amelio R, Arciola CR, Montanaro L, Baldassarri L.
792 2006. Relationship between biofilm formation, the enterococcal surface protein (Esp)
793 and gelatinase in clinical isolates of *Enterococcus faecalis* and *Enterococcus faecium*.
794 FEMS microbiology letters 256:145-150.

33

795 72. Toledo-Arana A, Valle J, Solano C, Arrizubieta MaJ, Cucarella C, Lamata M, Amorena
796 B, Leiva J, Penadés JR, Lasa I. 2001. The enterococcal surface protein, Esp, is involved
797 in *Enterococcus faecalis* biofilm formation. Applied and environmental microbiology
798 67:4538-4545.

73. Castillo-Ruiz M, Vinés ED, Montt C, Fernández J, Delgado JM, Hormazábal JC, Bittner
M. 2011. Isolation of a novel *Aggregatibacter actinomycetemcomitans* serotype b
bacteriophage capable of lysing bacteria within a biofilm. Applied and environmental
microbiology 77:3157-3159.

Machuca P, Daille L, Vinés E, Berrocal L, Bittner M. 2010. Isolation of a novel
bacteriophage specific for the periodontal pathogen *Fusobacterium nucleatum*. Applied
and environmental microbiology 76:7243-7250.

806 75. Szafrański SP, Winkel A, Stiesch M. 2017. The use of bacteriophages to biocontrol oral
807 biofilms. Journal of biotechnology 250:29-44.

76. Dalmasso M, De Haas E, Neve H, Strain R, Cousin FJ, Stockdale SR, Ross RP, Hill C.
2015. Isolation of a novel phage with activity against *Streptococcus mutans* biofilms.
PloS one 10:e0138651.

811 77. Hiroki H, Shiiki J, Handa A, Totsuka M, Nakamura O. 1976. Isolation of bacteriophages
812 specific for the genus *Veillonella*. Archives of oral biology 21:215-217.

813 78. Aljarbou AN, Aljofan M. 2014. Genotyping, morphology and molecular characteristics of
814 a lytic phage of *Neisseria* strain obtained from infected human dental plaque. Journal of
815 Microbiology 52:609-618.

816 79. Li X, Kolltveit KM, Tronstad L, Olsen I. 2000. Systemic diseases caused by oral
817 infection. Clinical microbiology reviews 13:547-558.

818 80. Scher JU, Abramson SB. 2011. The microbiome and rheumatoid arthritis. Nature
819 Reviews Rheumatology 7:569-578.

34

- 820 81. Qazi S, Harrison S, Self T, Williams P, Hill P. 2004. Real-time monitoring of intracellular Staphylococcus aureus replication. Journal of bacteriology 186:1065-1077. 821
- 82. Khalifa L, Gelman D, Shlezinger M, Dessal AL, Coppenhagen-Glazer S, Beyth N, Hazan 822 R. 2018. Defeating Antibiotic- and Phage-Resistant Enterococcus faecalis Using a 823 Phage Cocktail in Vitro and in a Clot Model. Front Microbiol 9:326. 824
- 825 83. Sedgley C, Lennan S, Clewell D. 2004. Prevalence, phenotype and genotype of oral enterococci. Oral microbiology and immunology 19:95-101. 826
- 84. Sedgley C, Nagel A, Shelburne C, Clewell D, Appelbe O, Molander A. 2005. Quantitative 827 828 real-time PCR detection of oral Enterococcus faecalis in humans. Archives of oral 829 biology 50:575-583.
- 85. Johnson EM, Flannagan SE, Sedgley CM. 2006. Coaggregation Interactions Between 830 831 Oral and Endodontic Enterococcus faecalis and Bacterial Species Isolated From Persistent Apical Periodontitis. Journal of endodontics 32:946-950. 832
- 833 86. Dahlen G, Blomqvist S, Almståhl A, Carlen A. 2012. Virulence factors and antibiotic 834 susceptibility in enterococci isolated from oral mucosal and deep infections. Journal of 835 oral microbiology 4.
- 87. Bourgogne A, Garsin DA, Qin X, Singh KV, Sillanpaa J, Yerrapragada S, Ding Y, Dugan-836 Rocha S, Buhay C, Shen H. 2008. Large scale variation in Enterococcus faecalis 837 illustrated by the genome analysis of strain OG1RF. Genome biology 9:R110. 838
- 839 88. Zeng J, Teng F, Weinstock GM, Murray BE. 2004. Translocation of Enterococcus 840 faecalis strains across a monolayer of polarized human enterocyte-like T84 cells. J Clin Microbiol 42:1149-54. 841
- 89. Jacob AE, Hobbs SJ. 1974. Conjugal transfer of plasmid-borne multiple antibiotic 842 resistance in Streptococcus faecalis var. zymogenes. Journal of Bacteriology 117:360-843 372. 844

845	90.	Van den Bogaard A, Mertens P, London N, Stobberingh E. 1997. High prevalence of
846		colonization with vancomycin-and pristinamycin-resistant enterococci in healthy humans
847		and pigs in The Netherlands: is the addition of antibiotics to animal feeds to blame?
848		Journal of Antimicrobial Chemotherapy 40:454-456.

874 **TABLES**

875 **Table 1. Bacterial strains used in the study.**

Bacterial strain	Source	Reference
E. faecalis		
EF1,EF2,EF3 OS16	Oral rinse-endodontic patient	(83) (84)
ER3/2s	Oral orthograde retreatment	(85)
OMGS3197, OMGS3198	Oral endodontic strains	(86)
OMGS3885, OMGS3919	Oral mucosal lesions	(86)
EF54	Non oral human isolate	(72)
OG1RF	Oral lab strain	(87)
OG1RF <i>epaB</i> TX5179; mutant harbouring an insertion in <i>epaB</i> (formerly <i>orfde4</i>)		(68)
OG1RF <i>epaB</i> TX5179 +pTX5249	Complementation plasmid build and strain constructed by Zeng et al (2004)	(88)
OG1RF OPDV; OG1RF derivative with deletions in oatA, pgdA, dltA and sigV	Constructed by Smith et al (2019)	(22)
<i>OPDV_11720::Tn2.5</i> ; A transposon mutant harbouring a mutation in <i>OG1RF_11720</i>	Isolated by Smith et al (22)	(22)
OPDV_11720::Tn2.5 + pTet-OG1RF_11720	Complementation plasmid built and strain constructed by Smith et al (22)	(22)
<i>OPDV_11715::Tn2.13</i> ; A transposon mutant harbouring a mutation in <i>OG1RF_11715</i>	Isolated by Smith et al (22)	(22)
OPDV_11715::Tn2.13 + pTet-OG1RF_11715	Complementation plasmid build and strain constructed by Smith et al (22)	(22)
OPDV_11714::Tn2.14; A transposon mutant harbouring a mutation in OG1RF_11714	Isolated by Smith et al (22)	(22)

37

Infection and Immunity

OPDV_11714::Tn2.14 + pTet-OG1RF_11714	Complementation plasmid build and strain constructed by Smith et al (2019)	(22)
<i>OPDV_11707::Tn2.8</i> ; A transposon mutant harbouring a mutation in <i>OG1RF_11714</i>	Isolated by Smith et al (2019)	(22)
OPDV_11707::Tn2.8 + pTet-OG1RF_11707	Complementation plasmid build and strain constructed by Smith et al (2019)	(22)
JH2-2	Non oral lab strain	(89)
E. faecium E1162	Clinical blood isolate; CC17	(90)

876

877

Table 2. Head and tail dimensions of isolated E. faecalis phages. At least three phage 878 particles were measured for each phage type and the mean value used for calculating 879 dimensions. 880

881

Phage	Head diameter (nm)	Tail length (nm)	
SHEF2	42.34 ± 1.0	231 ± 1.3	
SHEF4	45.60 ± 1.0	199.4 ± 0.8	
SHEF5	44.32 ±0.9	240.5 ± 1.5	
SHEF6	45.81 ± 0.4	250.6 ± 3.0	
SHEF7	41 ± 0.1	230 ± 2.4	

882

883

884 Table 3. Phage-host range of SHEF phages. (+) indicates a zone of clearance in both spot 885 and SAO screening tests and (-) no evidence of clearance. The final column indicates MLST designation established by sequencing according to http://efaecalis.mlst.net/ 886

 $\overline{\triangleleft}$

Accepted Manuscript Posted Online

Strain/Phage	SHEF2	SHEF4	SHEF5	SHEF6	SHEF7	MLST	887
OS16	+	-	+	+	+	173	
ER3/2s	+	-	-	+	+	21	
EF1	-	-	+	-	-	34	
EF2	-	+	-	-	-	283	
EF3	-	+	-	-	-	97	
EF54	+	-	-	+	+	381	
OMGS 3197	+	-	-	+	-	21	
OMGS 3198	+	-	-	-	-	55	
OMGS 3885	+	-	-	+	-	72	
OMGS 3919	+	-	-	+	+	97	
OG1RF	+	-	-	+	+	1	
V583	+	-	+	-	-	6	
JH2-2	-	-	+	-	-	8	
Total	9	2	4	7	5		

899 Figure Legends

Infection and Immunity

Figure 1A. Isolation of *E. faecalis* bacteriophage and plaque morphology. Images of bacterial plaques formed by the isolated phage in top-agar lawns of *E. faecalis* OS16 (SHEF2),

902 E. faecalis EF3 (SHEF4), E. faecalis EF2 (SHEF5) and E. faecalis OMGS3919 (SHEF6 and 7).

903 SHEF7 is also shown with *E. faecalis* OG1RF to illustrate plaque morphologies.

1B. Transmission electron micrographs of SHEF phage particles. Phage were negatively
 stained with 0.2 % uranyl acetate as described in methods section. Scale bars (100 nm).

1C. Restriction fragment length polymorphism (RFLP) analysis of extracted phage
chromosomal DNA SHEF2, 4, 5, , and 7 phages genomic DNA was digested with *Hind*III and
analysed by Agarose gel electrophoresis (inverted image shown alongside GeneRuler 1kb
ladder).

1D. Virion protein profiles of SHEF 2, 4, 5, 6, and 7 by SDS-PAGE with InsatntBlue staining.
The dominant protein band identified my MS/MS as the major capsid protein for SHEF2 at 36
KDa is indicated (*).

913

914 Figure 2. Genome organisation of *E. faecalis* lytic phages SHEF2, SHEF5, and SHEF4

2A. Images produced using SnapGene® Viewer 1.1.3 Software (DUF- conserved domains of
unknown function). Genome annotation corresponds to GenBank Accession numbers:
MF678788, MF678789, and MF678790 for SHEF2, 4 and 5 respectively; with colours
corresponding to predicted function as indicated in key.

919 **2B.** Mauve alignment of tail and lysis genes highlighting areas of conservation.

920

921 Figure 3. Molecular determination of SHEF2 phage adhesion using strain OG1RF.

3A. Schematic of the OG1RF *epa* core (purple) and variable locus (blue). Generated using
Snapgene (labelling according to Accession number NC_017316.1).

3B. Table showing qualitative results of spot-assay double layer agar infections of strains listed
with SHEF2 (+:infection; -: no infection) (for pictures see Fig S4).

3C. Phage adsorbtion assay for OG1RF and its isogenic mutant strains *epaB* and OPDV_11720 (all at 10⁸ CFU/ml bacteria) with SHEF2. Phage (input: 2x10⁶) were added for 24h before phage were enumerated in cell supernatants before and after treatment with 0.28 M NaCl by titre assay. ND-Not Determined (due to all cells being dead). This experiment was repeated twice in triplicate each time (mean shown), with one example displayed here.

3D. TEMs of infected OG1RF, epaB and _11720 mutants with SHEF2 at 30 mins post-infection-

932 arrows indicate adsorbed phage.

933

 \triangleleft

934 Figure 4. One step growth and adsorption rate characterisation of SHEF2.

4A. One-step growth curve of SHEF2 phage with *E. faecalis* OS16 as host. The two sets of data
represent samples treated with and without chloroform. Eclipse, burst and latent period are
labelled.

938 **4B**. Adsorption of SHEF2 phage to *E. faecalis* OS16 expressed as a % of total phage added.

4C. Transmission electron micrograph of strain OS16 + SHEF2 at 30 min post infection. black
arrows: spent heads and adsorbed phage; white arrow- un adsorbed phage.

941

Figure 5. Biofilm assay on polystyrene plates and tooth root slices.

943 **5A.** Bar charts represent biofilm growth as measured by Crystal violet staining (measured using 944 A570 of extracted stain, normalised to cell growth in each well, A600). Samples treated with live 945 phage are labelled: +SHEF2; while those with heat-killed: +SHEF2 (HK); strain names are as 946 elsewhere. Mean of 6 polystyrene microtitre wells per condition are shown with SD and students 947 t-test to compare conditions (P<0.0001). Experiments were conducted on three separate 948 occasions, one example shown.

5B. upper: photograph of tooth root slices in-situ treated with SHEF2 (+SHEF2) or strain EF54
only. The difference in colour represents resazurin reduction to resorufin, and is represented
quantitatively below (mean, SD from 3 readings), with Student's t-test was used to compare
between treated and untreated groups (p<0.0001).

5C. Stereo microscope (ST-left) and light microscope (LM-right, resazurin stained), images
represent the untreated group (upper) while the lower images SHEF2 –treated. Biofilm of *E. faecalis* colonies scattered on the root canal surface (RC) and dentinal surface (DS) of the ST
and LM images are shown, respectively.

Figure 6. Phage SHEF2 treatment of E. faecalis OS16-infected zebrafish embryos. 957 Zebrafish were infected systematically with E. faecalis OS16 strain or strain EF3 at a dose of 958 959 30,000 CFU at 30 hpf. After 2 hours embryos were injected with SHEF2 (SHEF2 LIVE) phage 960 or heat-inactivated (SHEF2(HK)) at an MOI 20 (in 2nl). Controls were also performed with phage only (SHEF2 LIVE or SHEF2(HK)) and PBS (2nl). Data are presented as Kaplan-Meier 961 962 survival plots (A,C) as well as bar-chart indicating mortality data at 72hpi or all conditons; Bars 963 represent means ± SD. Three independent experiments were performed (n=20 zebrafish per 964 condition per experiment). Statistical comparison between groups was performed using a log-965 rank test (A,C) or One-way Anova (B). (6D) Morphology of zebrafish embryos at 72hpi are shown injected with PBS, E. faecalis OS16 alone, SHEF2 LIVE alone or E. faecalis OS16 966

 \triangleleft

Accepted Manuscript Posted Online

 \mathbb{A}

967	followed by SHEF2 LIVE (D). Red arrows indicate symptoms of infection (eye and yolk sac
968	abnormalities, spinal curving and pericardial oedema). Scale bar = 500 μ m.

969

970

971

972

973




Figure 1

